IPAT is a highly selective ATP-competitive pan-AKT inhibitor that inhibits AKT signaling to downstream biomarkers and has demonstrated potent anti-tumor activities in pre-clinical studies in multiple types of cancer and a phase II clinical trial of breast cancer [18,31]. Here, AKT1 is linked to neoplasm.